Boston Scientific (NYSE:BSX) is facing a class action suit claiming the company engaged in robocalls advertising for seminars which directly promoted the company’s Spectra WaveWriter spinal cord stimulator, according to recently released court documents.
The plaintiff, Steven Sandoe of Weatherford, Texas, filed the class action complaint in the US District Court for the District of Massachusetts claiming that the Marlborough, Mass.-based company made “unsolicited, prerecorded voice sales calls to plaintiff despite his having registered his number on the National Do Not Call Registry to prevent such calls,” according to court documents.
The plaintiff claims he received two prerecorded calls this July advertising for seminars which were designed to directly promote the WaveWriter SCS, despite having no existing relationship with Boston Scientific and its products.
The suit suggests that there could be “hundreds, if not thousands of members of the Classes,” according to court documents.
Sandoe is seeking injunctive relief which would require that Boston Scientific stop making the calls to consumers without consent and to stop making calls to members of the DNC, as well as statutory damages to the class members, and legal costs, according to the documents.
Boston Scientific has not yet commented officially on the suit.
Earlier this month, Boston Scientific announced that it plans to submit the final technical module for the FDA premarket approval application for its Lotus Edge aortic heart valve system by the end of next week.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.